Latest news with #Mnemo
Yahoo
04-06-2025
- Business
- Yahoo
OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology
Figure_1 OSE Immunotherapeutics strengthens Growth Strategy: Accelerates key pillars of Inflammation and Immuno-Oncology Ignites strong momentum in immunology & inflammation pipeline through lusvertikimab development, leveraging a new predictive biomarker. Leads a new era in cancer vaccines with Tedopi® on track for registration. Drives company transformation through responsible governance: international development, rigorous financial planning and clinical execution. NANTES, France – June 4th, 2025, 8:00 am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today outlined the company's ambition for long-term growth and sustainable shareholder and societal value. Nicolas Poirier, CEO of OSE Immunotherapeutics notes: "OSE's grounding in solid science, our collaborative approach and a skilled workforce have resulted in a transformative two years, progressing our mission to bring breakthrough immunotherapies to the clinic. We are proud of our accomplishments, particularly delivering positive results for our lead assets, lusvertikimab and Tedopi®, which hold the potential to redefine standards of care across multiple diseases in I&I and I/O. We also secured new partnerships for our preclinical programs and significantly strengthened our financial position with over €90 million in new non-dilutive funding. OSE is positioned among Europe's leading biotechs. Now, it's time to build a more ambitious international company and unlock greater long-term value for all stakeholders.' OSE Immunotherapeutics' Board of Directors, led by Chairman, Didier Hoch, commented: 'Under the joint leadership of the Board and Executive Team, OSE has shown resilience and growth in a competitive biotech landscape. The company is entering a decisive phase. Our strategy is built on three pillars: maintaining scientific leadership, expanding strategic alliances, and ensuring disciplined financial management for sustainable growth. To achieve this, the company will explore various options, including business development, strategic alliances, international investments, and a potential Nasdaq listing. We are shaping the future by building an ambitious international biotech, driven by innovation creating lasting value for patients, employees, and shareholders.' New predictive biomarker with potential to revolutionize UC treatment, an emerging value lever for lusvertikimab Despite intensive therapeutic research in IBD, only 25–30% of UC patients currently achieve clinical remission, and this limitation—commonly referred to as the therapeutic ceiling (Vieujean S. Nature Reviews Gastroenterology, 2025)—persists across all approved therapies and drug classes in late-stage development. OSE research and translational teams, in collaboration with foundational model specialists, have identified a predictive biomarker that can isolate a subpopulation of patients (~30%) and offer significantly enhanced treatment outcomes, potentially achieving clinical remission rates exceeding 50%. This biomarker-driven approach was developed using advanced AI and transfer learning. The model was trained on multimodal data from millions of chronic inflammatory disease patients and refined with data from CoTikiS Phase 2 study. Importantly, biomarker-negative patients showed 0% clinical remission in this dataset, indicating no loss of treatment opportunity when prioritizing treatment based on biomarker status. This precision medicine approach could position lusvertikimab as a first-line therapy for the biomarker-positive population; a potential addressable market opportunity exceeding $3 billion across seven major markets. Next steps include prospective validation of this predictive biomarker through stratification in future clinical trials. Nicolas Poirier details: 'Our comprehensive dataset for lusvertikimab, with its novel upstream mechanism demonstrating clinical efficacy and good safety supports development in UC and other autoimmune diseases. The identification of a predictive biomarker is a breakthrough, suggesting that around 30% of UC patients could achieve remission rates over 50%. This reinforces lusvertikimab's potential as a monotherapy in UC and acts as an additional catalyst to accelerate development. We are designing a Phase 2b program to demonstrate efficacy by 2027, establish the dose for registrational studies, explore a subcutaneous formulation, and validate the predictive biomarker.' Commenting on OSE's progress in Tedopi, Nicolas Poirier adds: 'Earlier this week, we shared our progress with Tedopi® (link to press release). To summarize, our pivotal Phase 3 program in NSCLC with Tedopi® is progressing well, keeping us in the race to register the first therapeutic cancer vaccine. Enrolment is advancing across 144 clinical sites in Europe and North America and is on track to complete in the second half of 2026. The data readout is expected in 2027. The recent positive results in pancreatic cancer highlight the growing momentum behind therapeutic cancer vaccines. We are looking forward to additional Phase 2 readouts in combination with anti-PD1 from our ovarian and lung cancer trials in 2026.' Nicolas Poirier concludes: 'OSE is at the forefront of transformative scientific breakthroughs in areas of critical unmet medical need. I am convinced that the company is at a turning-point, with a clear international trajectory toward value creation and long-term impact. With strong science, strategic focus, and a robust diversified pipeline, OSE is uniquely positioned to deliver meaningful returns for shareholders—while transforming outcomes for patients worldwide.' DOCUMENTS MADE AVAILABLE TO SHAREHOLDERSThe convening brochure for the combined shareholders' meeting of June 25, 2025, now available on the Company's website ( is an essential tool for understanding the strategy pursued by the Board of Directors, informing shareholders and facilitating their voting decision. The related press release, presenting the context of the combined shareholders' meeting and the Board's position on all resolutions, is also available here: ABOUT COTIKIS The CoTikiS study, a 50-week randomized, double-blind, placebo-controlled trial, included a 10-week induction period evaluating two doses (450 mg or 850 mg) of lusvertikimab versus placebo; followed by a 24-week open label extension (OLE) with 850 mg infusions every four weeks; and a 16-week safety follow-up. Findings from the induction phase, presented at the 2025 ECCO congress, showed both doses met the primary efficacy endpoint (improvement in Modified Mayo Score at Week 10) and demonstrated significant results on secondary endpoints. The study highlights lusvertikimab's potential as a first-in-class monotherapy with a novel mechanism of action in the treatment of chronic and inflammatory diseases. Clinical and preclinical data were presented at ECCO 2025 and Digestive Disease Week (DDW) in May 2025, showing high rates of clinical and endoscopic remission, histological improvement and Histo-Endoscopic Mucosal Improvement (HEMI) with a favorable safety profile. Early efficacy signals in both biologic-naïve and experienced populations suggest rapid onset of effect, indicating potential as a first-line biologic or for patients resistant to anti-TNF and anti-IL-12/23 therapies. OLE data shows over 90% of UC patients who achieved a clinical response after 10 weeks maintained symptomatic remission for an additional 24 weeks, with 61% of those not in remission after 10 weeks achieving it after a further 24 weeks on the 850 mg dose. Lusvertikimab was well tolerated over the extended treatment period. ABOUT OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Follow us on Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachments Figure_1 EN_250604_Bold Strategic Vision press release_vf3
Business Wire
23-04-2025
- Business
- Business Wire
ID Logistics: Strong Year-start With Revenues Growth of +17.9% in Q1 2025
ORGON, France--(BUSINESS WIRE)--Regulatory News: ID Logistics (ISIN: FR0010929125, Mnemo: IDL), the European leader in contract logistics, today announced its revenues for the first quarter of 2025. Eric Hémar, Chairman and CEO of ID Logistics, comments: « Following on from the second half of 2024, ID Logistics recorded strong revenues growth in the first quarter of 2025. The Group continues to benefit from a diversified customer portfolio, the trust of global leaders, particularly in the consumer goods and e-commerce sectors, and a balanced business in terms of geographical exposure. Its contract logistics services are exclusively focused on domestic operations and are demonstrating good resilience against the changing global economic environment. Furthermore, the strong level of embedded growth and the sustained number of tenders should enable ID Logistics to continue its strong development in 2025 ». *see appendix Q1 2025 REVENUES GROWTH: +17.9% (+17.7% ON A LIKE-FOR-LIKE BASIS) ID Logistics posted revenues of €867.8 million in the first quarter of 2025, up 17.9%. Adjusted for a slightly favorable currency effect during the quarter, growth was 17.7% on a like-for-like basis compared to the first quarter of 2024. During the first quarter of 2025, we observed the following in particular: Very good business activity in France, with revenues up 15.8% (27% of Group revenues), continuing the strong rebound recorded in the fourth quarter of 2024; Revenues in Europe excluding France (47% of Group revenues) rose by 13.5% on a like-for-like basis; Strong momentum continued in the United States (18% of Group revenues), with revenues up significantly by 33.6% on a like-for-like basis; Growth of +17.4% on a comparable basis for Latin America and Asia (8% of Group revenue). During the quarter, ID Logistics launched six new projects. NEW CONTRACTS ID Logistics continued to respond to a sustained number of tenders during the 1 st quarter of 2025. By way of example, the Group won or started up the following new contracts: In France, following the launch of its first operation at the beginning of the year, ID Logistics continues its partnership with METRO, a leading food retailer for the food industry, with a new site located in La Brède, near Bordeaux. This 17,000 sq.m. tri-temperature warehouse handles dry, fresh and frozen products; In Germany, ID Logistics is strengthening its international partnership with a global e-commerce leader by opening a 68,000 sq.m. platform in the province of Hesse. This site will handle up to 2 million SKUs and will ultimately employ nearly 700 people; In the United States, in Wisconsin, the Group is opening a new 31,000 sq.m. site for the same leading e-commerce client, employing 350 people. ID Logistics is also continuing to support a global leader in beverages and snacks in the overhaul of its logistics in the United States and has started a new business in the State of Georgia on a 20,000 sq.m. site employing 80 people. In Brazil, ID Logistics is starting operations for one of the world's leading fashion companies, which is a new customer of the Group. Based in the state of Minas Gerais, this site will grow over the duration of the contract from 24,000 sq.m. and 150 employees to 43,000 sq.m. and 350 employees. OUTLOOK While taking into account changes in the global macroeconomic environment, ID Logistics believes it is well positioned overall to maintain its growth: the Group exclusively operates domestic logistics operations, serving leading international customers, mainly in the consumer goods and e-commerce sectors. Over the past few years, the Group has demonstrated its ability to adapt and the strength of its business model thanks to its customer centricity, its capacity for innovation and its diversified and geographically well-distributed business portfolio. ID Logistics intends to take advantage of its good level of embedded growth and the significant number of tenders to continue its rapid development. The Group also confirms its intention to use its strong investment capacity to pursue external growth opportunities. NEXT PUBLICATION Revenues for 2025 2 nd quarter: July 23, 2025, after market close. ABOUT ID LOGISTICS: ID Logistics, headed by Eric Hémar, is an international contract logistics group with revenues of €3.3 billion in 2024. ID Logistics manages nearly 450 sites in 18 countries representing, more than 9 million m² operated in Europe, America, Asia and Africa, with 42,000 employees. With a customer portfolio balanced between distribution, e-commerce and consumer goods, ID Logistics is characterized by offers involving a high level of technology. Since its creation in 2001, the Group has developed a social and environmental approach through a number of original projects, and is now firmly committed to an ambitious CSR policy. ID Logistics shares are listed on the Euronext regulated market in Paris and are included in the SBF 120 index (ISIN code: FR0010929125, Mnemo: IDL). APPENDIX *see below CHANGE ON A LIKE-FOR-LIKE BASIS Changes in revenues on a like-for-like basis reflect the organic performance of the ID Logistics Group, excluding the impact of: - changes in the scope of consolidation: the contribution to revenues of companies acquired during the period is excluded from this period, and the contribution to revenues of companies sold during the previous period is excluded from this period; - changes in applicable accounting principles; - variations in exchange rates, by calculating revenues for different periods on the basis of identical exchange rates: thus, published data for the previous period are converted using the exchange rate for the current period. Change in revenues from reported to comparable data
Yahoo
29-01-2025
- Business
- Yahoo
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy
OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy Nantes and Paris - France, January 29, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision immunology, announce a strategic collaboration to harness Scienta Lab's advanced AI platform for modeling inflammatory diseases and identifying predictive biomarkers of efficacy for immunotherapies. Under this agreement, Scienta Lab will deploy EVA, its proprietary AI-powered multimodal foundation model dedicated to translational research in immunology, to discover multimodal signatures that can pinpoint predictive biomarkers for immunotherapy in immuno-inflammation. The aim is to identify patient subtypes likely to respond to specific therapeutic options and extract associated multimodal biomarkers through explainable AI. This initiative represents a significant step in precision medicine, supporting the development of tailored immunotherapies that drive better outcomes for patients with immune-mediated inflammatory diseases. Camille Bouget, CEO and Co-founder of Scienta Lab, stated: "Given the complex and heterogeneous nature of immuno-inflammatory pathologies, precisely targeted therapeutic interventions are essential for achieving optimal patient outcomes. We are very pleased to partner with OSE Immunotherapeutics, a leading European biotech, to leverage EVA in pursuit of this objective. Our aim is to uncover multimodal signatures that integrate systemic and local factors to stratify immuno-inflammatory diseases into distinct subtypes. The partnership is set to generate significant scientific and economic value for both companies while advancing our shared mission of driving innovation in precision immunology.' Nicolas Poirier, CEO of OSE Immunotherapeutics, commented: "We are excited about this new collaboration as we continually seek to integrate pioneering AI approaches and technologies to develop first-in-class products in immuno-oncology and immuno-inflammation. In today's fast-paced world, speed is the new currency, and an AI solution capable of identifying predictive biomarkers in immuno-inflammation will be pivotal in our research and clinical development efforts across various chronic inflammatory and autoimmune diseases. This partnership could help speed up our innovation process, potentially leading to more personalized treatments that greatly improve patient health and quality of life.' This collaboration builds on OSE Immunotherapeutics' commitment to integrating AI solutions that enhance the Company's research and development efforts. In 2020, OSE Immunotherapeutics entered into agreement with MAbSilico to utilize AI technology for the design and discovery of antibody drugs. This ongoing partnership aims to aid and speed-up therapeutic antibody discovery, reduce the risk of failure, and expedite preclinical development. ABOUT SCIENTA LAB Scienta Lab is a deeptech company harnessing artificial intelligence to pioneer AI-powered Precision Immunology. With its unique and proprietary technology based on a foundation model, Scienta Lab leverages multimodal data to support translational research and clinical development in immuno-inflammation. Scienta Lab research activities, led in partnership with top-tier academic institutions, pharmaceutical and biotech companies, are regularly featured in medical journals and international congresses. For more information, visit Contact Camille OSE IMMUNOTHERAPEUTICS OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on information about OSE Immunotherapeutics assets is available on the Company's website: Fiona Dé French Media Contact FP2COMFlorence Portejoiefportejoie@ 6 07 768 283U.S. Media ContactRooney Partners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statementsThis press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2024, including the annual financial report for the fiscal year 2023, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250129_OSE_Scienta Lab_vf
